Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03000855
Other study ID # CRE-2016.193-T
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date December 2016
Est. completion date December 2022

Study information

Verified date August 2023
Source Chinese University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

EUS - guided choledocho-duodenostomy (ECDS) is an established option for bile duct drainage in unresectable malignant distal CBD strictures when endoscopic retrograde cholangiopancreatography (ERCP) fails. However, how primary ECDS compares with ERCP with covered self-expanding metallic stents (CSEMS) in unresectable malignant distal CBD strictures is uncertain. The aim of the current study is to compare primary ECDS versus ERCP with CSEMS in unresectable malignant distal CBD strictures. We hypothesis that ECDS is associated with a higher 1-year stent patency rate.


Description:

Malignant biliary obstruction is a common sequela of pancreatic cancers or distal bile duct cancers, and its development can hinder the use of chemotherapy, decrease patient quality of life and decrease survival. Malignant biliary obstruction is traditionally palliated with ERCP with metallic stent insertion. However, these stents are prone to obstruction due to tumour ingrowth. In addition, ERCP may not always be possible due to tumour obstruction and percutaneous biliary drainage may be required. Recently, ECDS has been described as an alternative to percutaneous biliary drainage in patients with failed ERCP. The procedure is also associated with potential advantages as compared to conventional ERCP. In particular, the risk of tumour ingrowth into the stent placed after ECDS is low and stent patency rates may be better than ERCP. Thus, the aim of the current study is to compare primary ECDS versus ERCP with CSEMS in unresectable malignant distal CBD strictures.


Recruitment information / eligibility

Status Completed
Enrollment 77
Est. completion date December 2022
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years old with informed consent - Histologically (preferred) or radiologically confirmed distal malignant bile duct tumors - Inoperability by staging, comorbidities or patient wishes - Distal tumors 2cm away from the portal hilum - Bilirubin > 50umol/L at diagnosis Exclusion Criteria: - Multiple hepatic metastases with significant blockage of one or more liver segments (if no segment blockage, metastasis is not an exclusion criteria) - Presence of main portal vein thrombosis - Prior SEMS placement - Intraductal papillary mucinous carcinomas - Prior Billroth II or roux-en Y reconstruction - History of bleeding disorder or use of anticoagulation - Child's B/C cirrhosis - Pregnancy - Performance status ECOG =3 (confined to bed / chair > 50% waking hours) - Presence of other malignancy - Life expectancy < 3months

Study Design


Intervention

Procedure:
EUS-guided choledocho-duodenostomy
The CBD would be identified by a linear echoendoscope and a suitable puncture site in the bulb of the duodenum would be located. The common bile duct would be punctured with a 19-gauge needle and the position would be confirmed by aspiration of bile and contrast injection. A 0.025" or 0.035" guide wire would be passed through the needle in to the CBD. A fully covered metal stent would then be inserted after track dilation.
Endoscopic retrograde cholangiopancreatography with covered metallic stent
After cannulation of the CBD, a cholangiography would be performed to assess the diameter of the CBD, the length and position of the biliary stricture. The endoscopist would decide on the appropriate size of SEMS to be placed. The stents should be visible from the duodenal lumen after deployment.

Locations

Country Name City State
Australia Royal Prince Alfred Hospital Sydney
Belgium The University of Leuven Leuven
China Chinese University of Hong Kong Hong Kong Hong Kong
Denmark Aarhus University Hospital Aarhus
Japan Tokyo Medical University Hospital Tokyo
Japan Wakayama Medical University School of Medicine Wakayama

Sponsors (3)

Lead Sponsor Collaborator
Chinese University of Hong Kong Kinki University, Tokyo Medical University

Countries where clinical trial is conducted

Australia,  Belgium,  China,  Denmark,  Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary stent patency rate Stent dysfunction is defined as radiology or endoscopy confirmed stent obstruction. 1-year
Secondary Technical success Technical success is defined as the ability to access and drain the CBD by placement of a stent. 1year
Secondary Clinical success Clinical success is defined as >30% drop in bilirubin levels 1 year
Secondary Adverse events Adverse events related to the endoscopic procedures would be graded according to the lexicon of endoscopic adverse events 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT04941924 - The ID- RFA Trial: A Trial of Intraductal Radio-frequency Ablation (ID-RFA) Plus Biliary Stenting Versus Biliary Stenting Alone for the Treatment of Malignant Biliary Obstruction. N/A
Active, not recruiting NCT03672019 - A Quality of Life Study in Patients Undergoing Percutaneous Biliary Drainage
Recruiting NCT05220475 - A Comparison of a Fully Covered Self-expandable Metal Stent With an External Anchoring Plastic Stent and Uncovered Stent N/A
Completed NCT02001779 - IRS(Irradiation Stent) vs. CS(Conventional Stent) Insertion in Inoperable Malignant Biliary Obstruction N/A
Not yet recruiting NCT06375928 - EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial) N/A
Not yet recruiting NCT06375954 - EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial) N/A
Recruiting NCT05786326 - Multihole Fully Covered Metallic Stents in the Management of Malignant Biliary Obstruction N/A
Not yet recruiting NCT06375967 - EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial) N/A
Completed NCT01869894 - A Prospective Randomized Study for Efficacy of Uncovered Double Bare Metallic Stent Compared to Uncovered Single Bare Metallic Stent in Malignant Biliary Obstruction N/A
Not yet recruiting NCT05804201 - EUS-guided Hepatico-gastrostomy With Hot Giobor N/A
Recruiting NCT01686425 - Percutaneous Transhepatic Cholangiography Versus Endoscopic Ultrasound Guided Biliary Drainage N/A
Recruiting NCT03215108 - Comparison Between Novel Flower-type Covered Stent and Conventional Covered Stent N/A
Recruiting NCT04898777 - EUS-Guided Choledochoduodenostomy Versus ERCP for Primary Biliary Decompression in Distal Malignant Biliary Obstruction N/A
Recruiting NCT05169398 - EUS-guided Hepatico-gastrostomy Using a Novel Lumen Apposing Metal Stent N/A
Enrolling by invitation NCT05233293 - Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma N/A
Completed NCT03812250 - EUS-guided Biliary Drainage vs. ERCP Assisted Transpapillary Drainage for Malignant Biliary Obstruction N/A
Recruiting NCT01073514 - Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction N/A
Recruiting NCT05142839 - Palliation of Gastric Outflow Obstruction in Case of Concomitant Biliary Obstruction. N/A
Recruiting NCT05729867 - Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC N/A
Completed NCT04405752 - Evaluation of a New Metal Biliary Stent of 12-mm Diameter: a Case Control Study